ArticleJTO clinical and research reports2022

Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With

Yi-Long Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.